Literature DB >> 7739627

Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses.

K Arahata1, T Ishihara, H Fukunaga, S Orimo, J H Lee, K Goto, I Nonaka.   

Abstract

To investigate the nature of the inflammatory response in facioscapulohumeral muscular dystrophy (FSHD), we analyzed mononuclear cells in muscle sections obtained from 18 FSHD patients and 8 controls. Monoclonal antibodies reactive for T cells, T cell subsets, B cells, and NK cells were used for cell typing. Macrophages were identified by acid phosphatase reaction. The localization of perforin, granzyme A, MHC-I and -II, dystrophin, and alpha-actinin antigens was also examined. We found that all FSHD patients, both familiar and sporadic cases, had greater amounts of mononuclear cellular infiltrates in muscle than controls, in whose specimens only few extra vascular mononuclear cells were counted. Seventy-two percent (13 of 18) of the patients had more than 50 inflammatory mononuclear cells per 1000 muscle fibers, and 33% (6 of 18) patients had numerous inflammatory cells exceeding 600 per 1000 muscle fibers (1835 +/- 482 SE). Nonnecrotic fibers invaded by mononuclear cells with either T8+, perforin+, or granzyme A+ were not observed in FSHD, while a few degenerating fibers were superficially invaded by T cells and macrophages. Occasional T cells were observed moving through the blood vessel wall. The increased number of necrotic fibers was paralleled by an increased number of inflammatory cells (r = 0.783, P = 0.0001). Genetic analysis, using the probes p13E-11, pFR-1, D4S139, and D4S163, was done in 6 patients (3 familiar, 3 sporadic) who had numerous inflammatory infiltrates. These 6 patients had small (< 28 kb) EcoRI fragments associated with the disease, and the disease was linked to 4q35. These results suggest that, in chromosome 4-linked FSHD: (1) inflammatory changes in muscle are a common histological feature; (2) mononuclear cellular infiltrates may enhance muscle fiber damage; but (3) T-cell-mediated cytotoxicity directed against muscle fibers is unlikely. We speculate that the immune effector mechanism in FSHD is different from that in previously reported inflammatory myopathies and Duchenne muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7739627

Source DB:  PubMed          Journal:  Muscle Nerve Suppl


  47 in total

1.  Contractions of D4Z4 on 4qB subtelomeres do not cause facioscapulohumeral muscular dystrophy.

Authors:  Richard J F L Lemmers; Mariëlle Wohlgemuth; Rune R Frants; George W Padberg; Eva Morava; Silvere M van der Maarel
Journal:  Am J Hum Genet       Date:  2004-10-04       Impact factor: 11.025

2.  Genetic counseling and testing for FSHD (facioscapulohumeral muscular dystrophy) in the Israeli population.

Authors:  Miri Yanoov-Sharav; Esther Leshinsky-Silver; Sarit Cohen; Chana Vinkler; Marina Michelson; Tally Lerman-Sagie; Mira Ginzberg; Menahem Sadeh; Dorit Lev
Journal:  J Genet Couns       Date:  2011-11-23       Impact factor: 2.537

Review 3.  Immunobiology of Inherited Muscular Dystrophies.

Authors:  James G Tidball; Steven S Welc; Michelle Wehling-Henricks
Journal:  Compr Physiol       Date:  2018-09-14       Impact factor: 9.090

4.  Exome sequencing identifies a novel SMCHD1 mutation in facioscapulohumeral muscular dystrophy 2.

Authors:  Satomi Mitsuhashi; Steven E Boyden; Elicia A Estrella; Takako I Jones; Fedik Rahimov; Timothy W Yu; Basil T Darras; Anthony A Amato; Rebecca D Folkerth; Peter L Jones; Louis M Kunkel; Peter B Kang
Journal:  Neuromuscul Disord       Date:  2013-08-31       Impact factor: 4.296

5.  DUX4 Suppresses MHC Class I to Promote Cancer Immune Evasion and Resistance to Checkpoint Blockade.

Authors:  Guo-Liang Chew; Amy E Campbell; Emma De Neef; Nicholas A Sutliff; Sean C Shadle; Stephen J Tapscott; Robert K Bradley
Journal:  Dev Cell       Date:  2019-07-18       Impact factor: 12.270

Review 6.  Facioscapulohumeral Muscular Dystrophy.

Authors:  Jeffrey M Statland; Rabi Tawil
Journal:  Continuum (Minneap Minn)       Date:  2016-12

7.  High specificity of myositis specific autoantibodies for myositis compared with other neuromuscular disorders.

Authors:  G J D Hengstman; L van Brenk; W T M Vree Egberts; E L van der Kooi; G F Borm; G W A M Padberg; W J van Venrooij; B G M van Engelen
Journal:  J Neurol       Date:  2005-02-23       Impact factor: 4.849

8.  DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1.

Authors:  Manjusha Dixit; Eugénie Ansseau; Alexandra Tassin; Sara Winokur; Rongye Shi; Hong Qian; Sébastien Sauvage; Christel Mattéotti; Anne M van Acker; Oberdan Leo; Denise Figlewicz; Marietta Barro; Dalila Laoudj-Chenivesse; Alexandra Belayew; Frédérique Coppée; Yi-Wen Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-05       Impact factor: 11.205

Review 9.  Drug treatment for facioscapulohumeral muscular dystrophy.

Authors:  M R Rose; R Tawil
Journal:  Cochrane Database Syst Rev       Date:  2004

10.  Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy.

Authors:  E L van der Kooi; J S Kalkman; E Lindeman; J C M Hendriks; B G M van Engelen; G Bleijenberg; G W Padberg
Journal:  J Neurol       Date:  2007-03-14       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.